Sector News

Astellas sets up immune tolerance JV in $760m deal

June 4, 2015
Life sciences
Japanese drugmaker Astellas and Swiss biotech Anokion have hooked up in a deal worth $760 million to create a new US-based firm focused on developing novel immune tolerance therapeutics.
 
Kanyos Bio, which is headquartered in Cambridge, Massachusetts, will initially work on clinical candidates for type I  diabetes and coeliac disease, although Astellas has the option to add a third autoimmune indication.
 
The firm will utilise Anokion’s tolerance-inducing technology shown to induce immune tolerance to protein drugs and autoimmune antigens in animal models, in an approach that the firm says “can be translated to virtually any protein in a myriad of clinical indications”. 
 
Astellas will provide non-dilutive research funding to Kanyos and holds an option to snap up the firm after reaching certain milestones, and will also take part in a $16 Million equity financing for new group alongside existing Anokion investors to secure some early cash.
 
By Selina McKee
 
Source: Pharma Times

comments closed

Related News

October 2, 2022

GSK names Julie Brown, a 25-year AstraZeneca veteran, its first woman CFO

Life sciences

Five years ago, GSK made headlines when it hired Emma Walmsley to become the first woman to run a major pharmaceutical company. Now the Big Pharma has brought in another woman to control the company’s finances. Julie Brown will be GSK’s next chief financial officer. Brown, currently the chief operating and financial officer at fashion and beauty brand Burberry Group, is set to replace Iain Mackay.

October 2, 2022

Moderna creates new launch preparation role, poaches Novartis exec as manufacturing lead

Life sciences

Moderna created a new role responsible for “building out the company’s organization to support its growing pipeline.” Starting first thing 2023, Juan Andres, Moderna’s manufacturing head, will step into this new role under the title president of strategic partnerships and enterprise expansion, the company said Thursday.

October 2, 2022

Torrent Pharma to acquire Curatio for $245.16m

Life sciences

The latest takeover is anticipated to boost the presence of Torrent in the dermatology segment. Indian company Torrent Pharmaceuticals has signed a definitive agreement for the complete acquisition of Curatio Healthcare for $245.16m (Rs20bn).